NPS Pharmaceuticals Seeks Bounce from Natpara Phase III
One week after shares of NPS Pharmaceuticals Inc. were drubbed over safety concerns about the GLP-2 analogue Gattex (teduglutide) in short bowel syndrome, the company sought a ray of sunshine with positive top-line results from its pivotal Phase III REPLACE study of Natpara (NPSP558), a bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients. (See BioWorld Today, Nov. 1, 2011.)
In an intent-to-treat analysis, NPS reported that 53 percent (48/90) of Natpara-treated patients achieved the primary endpoint vs.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST